Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.36T
Market cap1.36T
Price-Earnings ratio
46.89
Price-Earnings ratio46.89
Dividend yield
0.47%
Dividend yield0.47%
Average volume
3.23M
Average volume3.23M
High today
$1,449.64
High today$1,449.64
Low today
$1,419.81
Low today$1,419.81
Open price
$1,432.99
Open price$1,432.99
Volume
2.08M
Volume2.08M
52 Week high
$1,460.00
52 Week high$1,460.00
52 Week low
$850.51
52 Week low$850.51

Stock Snapshot

With a market cap of 1.36T, Eli Lilly(LLY) trades at $1,439.59. The stock has a price-to-earnings ratio of 46.89 and currently yields dividends of 0.47%.

During the trading session on 2026-11-14, Eli Lilly(LLY) shares reached a daily high of $1,449.64 and a low of $1,419.81. At a current price of $1,439.59, the stock is +1.4% higher than the low and still -0.7% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 2.08M, versus its average volume of 3.23M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,460.00 and a low of $850.51.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,460.00 and a low of $850.51.

LLY News

Financial Times 44m
Makers of obesity drugs hit back at claims of negative side effects - Financial Times

...

Makers of obesity drugs hit back at claims of negative side effects - Financial Times
Simply Wall St 4h
Eli Lilly Faces New Vision Loss Lawsuits As Pipeline Milestones Keep Coming

Eli Lilly (NYSE:LLY) faces new lawsuits alleging its GLP-1 drug Mounjaro causes irreversible vision loss linked to NAION. Regulators in several countries issue...

Eli Lilly Faces New Vision Loss Lawsuits As Pipeline Milestones Keep Coming
TipRanks 19h
Eli Lilly Advances Early ALS Drug Study, but Investors Must Wait for Data

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is preparing a Phase 1b study of LY38738...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Wall Street Journal 24h
Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
Seeking Alpha 2d
Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds

Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds Nov 12, 2026, 5:18 PM ET Eli Lilly and Company (LLY) Stock By : Jonathan Block...

Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds
The Motley Fool 2d
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It

Artificial intelligence (AI) is changing every sector, but the magnitude of its impact isn't identical across different industries. Perhaps many investors belie...

Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
TipRanks 2d
Eli Lilly Stock Jumps as China Approves Its Weight-Loss Pill

Eli Lilly’s (LLY) stock was up as much as 3% on Nov. 12 after China’s medicine regulator approved the sale of the company’s weight-loss pill in the country of 1...

Benzinga 2d
Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report

Eli Lilly and Company (NYSE:LLY) has reportedly won Chinese approval for orforglipron, becoming the first company to offer a GLP-1 weight-management pill in the...

Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report
TipRanks 2d
Eli Lilly announces Orforglipron approved by China’s NMPA

Eli Lilly (LLY) China announced that its Orforglipron has been approved by China’s National Medical Products Administration, NMPA, for the launch of a Category...

Simply Wall St 2d
Eli Lilly Stock Looks Reasonable After Its Very Large Five Year Run

has become one of the most closely watched stocks in big pharma after a strong multi year run, and the key question now is whether the cash the business can gen...

Eli Lilly Stock Looks Reasonable After Its Very Large Five Year Run

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.